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Abstract
Acinetobacter baumannii is an important nosocomial pathogen, commonly causing infections in immunocompromised patients. It is
increasingly reported as a multidrug-resistant organism, which is alarming because of its capability to resist all available classes of antibiotics
including carbapenems. The aim of this study was to examine the genetic and epidemiological diversity of A. baumannii isolates from
paediatric cancer patients in Egypt, by sequencing the intrinsic blaOXA–51-like gene, genotyping by pulsed-ﬁeld gel electrophoresis and
multi-locus sequence typing in addition to identifying the carbapenem-resistance mechanism. Results showed a large diversity within the
isolates, with eight different blaOXA-51-like genes, seven novel sequence types and only 28% similarity by pulsed-ﬁeld gel electrophoresis. All
three acquired class-D carbapenemases (OXA-23, OXA-40 and OXA-58) were also identiﬁed among these strains correlating with
resistance to carbapenems. In addition, we report the ﬁrst identiﬁcation of ISAba2 upstream of blaOXA-51-like contributing to high-level
carbapenem resistance. This indicates the presence of several clones of A. baumannii in the hospitals and illustrates the large genetic and
epidemiological diversity found in Egyptian strains.
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Introduction
Acinetobacter baumannii has emerged as an important nosoco-
mial pathogen in the past decade, which in recent years has
developed into a multidrug-resistant problematic pathogen [1].
Acinetobacter baumannii is an opportunistic pathogen, fre-
quently isolated from immunocompromised patients with
prolonged hospitalization [2]. As a consequence of immuno-
ablative treatment, patients with cancer are at risk of
developing A. baumannii infections, including sepsis, respira-
tory, wound and tissue infections, in addition to urinary tract
infections [2,3].
A major concern in A. baumannii is its worldwide clonal
expansion and its ability to survive and disseminate in hospitals,
with numerous outbreaks reported from different regions of
the world [4]. Acinetobacter baumannii is notably resistant to
extreme environmental conditions, such as dryness, and can
survive on surfaces for a long time, hence facilitating its spread
[1,4].
Resistance to carbapenems, the b-lactam drugs of last
resort in treating A baumannii infections, has been attributed
to the expression of carbapenem-hydrolysing oxacillinase
genes, blaOXA23, blaOXA-40 and blaOXA58, which are usually
plasmid encoded [5,6]. The ubiquitous, chromosomally
encoded blaOXA-51-like gene only confers resistance when an
Insertion Sequence (IS) is present upstream of the gene [7].
Due to the prevalence of A. baumannii across the world,
suitable typing methods to investigate the epidemiological
distribution of the organism have been developed such as
ribotyping, ampliﬁed fragment length polymorphisms,
pulsed-ﬁeld gel electrophoresis (PFGE) and, more recently,
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Multi-Locus Sequence Typing (MLST) [8]. Additionally, ampli-
ﬁcation and sequencing of the ubiquitous blaOXA-51-like gene has
also been used to determine clonal groups from diverse
worldwide sources [7,8].
Limited data were available concerning the epidemiological
distribution of A. baumannii in the Middle East but, in the past
few years, reports of strains in the United Arab Emirates, Iraq,
Kuwait and Egypt harbouring diverse resistance mechanisms
have emerged [9–12]. The aim of this study was to investigate
the epidemiological and molecular diversity of A. baumannii
strains isolated from two cancer centres in Cairo, Egypt.
Materials and Methods
Isolate identiﬁcation
Thirty-four non-duplicate A. baumanniiwere obtained from two
centres; The Children’s Cancer Hospital (CCH) and The
National Cancer Institute (NCI), both located in Cairo, Egypt,
from 2010 to 2011. Initial identiﬁcation and susceptibility testing
was done using VITEK and Phoenix automated machines.
Genotypic identiﬁcation was carried out by restriction analysis
of 16s-23s rRNA spacer sequences using AluI and NdeII [13].
Detection of blaOXA-51-like genes
The intrinsic blaOXA-51-like genes were ampliﬁed for A. bau-
mannii isolates using primers: OXA69A and B [7]. Products
were puriﬁed using a QIAquick PCR Puriﬁcation Kit (Qiagen,
Crawley, UK) and sequenced in both directions on a 3730
DNA Analyzer (Applied Biosystems, Warrington, UK). For
isolates yielding a larger product size, a PCR was performed to
screen for the associated upstream environment using primers
FxOxa-F and FxOxa-R [14].
Detection of class D oxacillinases and genetic environment
Isolates were screened for the presence of acquired OXA
carbapenemases by Multiplex PCR, as previously described
[15]. Isolates positive for the individual OXA groups were
subsequently ampliﬁed and sequenced using primers for the full
sequence of the genes. Associated genetic environment was
also ampliﬁed and sequenced. Primers used are listed in
Table 1.
Minimum inhibitory concentrations
The MIC of imipenem and meropenem were determined using
an agar double dilution technique according to the British
Society of Antimicrobial Chemotherapy (BSAC) guidelines
[16]. Pseudomonas aeruginosa NCTC 10662, Escherichia coli
NCTC 10418 and Staphylococcus aureus NCTC 6571 were
used as control strains.
Pulsed-ﬁeld gel electrophoresis
All isolates were typed by PFGE according to the procedure
previously described by Seifert et al. [17]. Brieﬂy, plugs were
incubated in 30 U ApaI at 37° overnight, and subsequently run
on 1% pulsed-ﬁeld-certiﬁed agarose gel (Bio-Rad, Hertford-
shire, UK) in 0.5 9 TBE buffer with an initial pulse of 5 s and a
ﬁnal pulse of 20 s for 20 h. The gels were stained with Gel-Red
solution and visualized using the DIVERSITY DATABASE (Bio-Rad)
software image-capturing system.
Multi-locus sequence typing
The PCR for the seven housekeeping genes: gltA, gyrB, gdhB,
rpoD, recA, gpi and cpn60 was performed according to the
scheme developed by Bartual et al. [18]. Products were
puriﬁed and sequenced as described above. MLST was per-
formed for ten isolates, representatives of the blaOXA-51-like
gene variants identiﬁed. If isolates from different hospitals
harboured similar blaOXA-51-like genes, an isolate from each
hospital was selected randomly for comparison. Isolates
chosen for MLST were: 8357, 9925-SAM, 1780, 634, 21174,
22055, 161, P38-YSF, P67-AZ and 14611.
TABLE 1. List of primers used in
this study
Primer name Sequence 5′–3′ Use Reference
16s-23s rRNA F TTGTACACACCGCCCGTCA Identiﬁcation [13]
16s-23s rRNA R GGTACTTAGATGTTTCAGTTC
Oxa69-A CTAATAATTGATCTACTCAAG blaOXA-51-like ampliﬁcation and sequencing [7]
Oxa69-B CCAGTGGATGGATGGATAGATTATC
FxOxaF GATACCAGACCTGGCAACAT Upstream environment of blaOXA-51-like
gene
[14]
FxOxaR GCACGAGCAAGATCATTACC
blaOXA-23 F GATGTGTCATAGTATTCGTCG Whole gene-sequence of blaOXA23 [25]
blaOXA-23 R TCACAACAACTAAAAGCACTG
ISAba1A GTGCTTTGCGCTCATCATGC Upstream environment of blaOXA23 [26]
SM2 AAGTGTCTATATTCTCACC Upstream environment of blaOXA58
ISAba3-F CAATCAAATGTCCAACCTGC Upstream environment of blaOXA58
OXA-58A CGATCAGAATGTTCAAGCGC Whole gene sequence of blaOXA58 [22]
OXA-58B ACGATTCTCCCCTCTGCGC
OXA-24FF ATGAAAAAATTTATACTTCCTA
TATTCAGC
Whole gene sequence of blaOXA24 [27]
OXA-24RR TTAAATGATTCCAAGATTTTCTAGC
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Results
Diversity of blaOXA-51-like genes
All isolates were conﬁrmed as A. baumannii, and sequencing of
the intrinsic blaOXA-51-like revealed the presence of eight
different genes: blaOXA-64, blaOXA-65, blaOXA-66, blaOXA-69,
blaOXA-71, blaOXA-78, blaOXA-94 and blaOXA-89 (Table 2).
blaOXA-65 was the most prevalent, found in 14 isolates,
obtained from both hospitals. blaOXA-64 is now commonly
found in the Middle East (A. Al Hasan, and S.G.B. Amyes,
unpublished results; [9]), it was found in seven isolates
obtained from both hospitals. There were representatives
from the three worldwide clones (formally known as the
European clones). blaOXA-66 was found in four isolates, three
of which were from CCH. blaOXA-69 was identiﬁed in two
isolates at the intensive care unit (ICU) of CCH and were part
of an A. baumanniii outbreak in early 2011. blaOXA-71 was found
in two isolates from different hospitals. blaOXA-78 and blaOXA-89
were both found in strains from CCH, whereas blaOXA-94 was
from two isolates from NCI, recovered from the same ﬂoor,
1 day apart.
Insertion sequences associated with blaOXA-51-like
Sequencing upstream of the blaOXA-51-like gene, blaOXA-89 in
isolate 22055 revealed the presence of ISAba2, with the -35
(ttatat) and -10 (ttgtaggat) promoters 29 bp apart, and located
102 bp and 82 bp upstream of blaOXA-89, respectively. No
other insertion sequences were identiﬁed upstream of the
blaOXA-51-like genes.
PFGE
The PFGE analysis revealed a large diversity within the
strains. Some isolates with similar blaOXA-51-like genes had
very distinct PFGE patterns, suggesting no epidemiological
similarity between the strains. As seen in Figure 1, only six
isolates harbouring blaOXA-65 show > 80% similarity in their
PFGE pattern. Additionally, blaOXA-64 isolates all shared less
than 80% similarity. Even isolates with blaOXA-94, which were
collected from patients on the same ﬂoor of the same
hospital 1 day apart, had distinct PFGE patterns. On the
other hand, the blaOXA-71 containing isolates, although from
different hospitals, had similar PFGE patterns. The similarity
for all the isolates was calculated by Dice coefﬁcient to be
28.7%.
TABLE 2. Isolates harbouring blaOXA-51-like genes, with isolation details. carbapenem-hydrolysing class D b-lactamase (CHDL)
genes, minimum inhibitory concentration (MIC) and sequence type. Isolates in bold were in the A. baumannii outbreak in early
2011
Isolation details CHDL b-lactamase gene MIC (mg/L)
Sequence typeIsolate no. Date of sample Hospital Location Site of isolate blaOXA-51-like blaOXA-23 blaOXA-58 blaOXA-40 IMI MER
7947 17/05/2010 CCH ICU Wound 64 0.25 0.06
12435 23/07/2010 CCH ICU Blood 64 + 16 32
14298 22/08/2010 CCH ICU Catheter tip 64 + 8 2
8357 5/29/2011 CCH DSCH CVP Blood 64 8 16 ST408
4248 15/03/2010 CCH IP-5C CVP tip 65 + 8 4
4842 23/03/2010 CCH ICU CVP tip 65 + 64 32
9930 15/06/2010 CCH ICU Blood and CVP 65 + 32 16
10262 19/06/2010 CCH ICU CVP 65 + 64 128
15094 05/09/2010 CCH IP-4B Urine 65 0.25 0.12
15324 09/09/2010 CCH IP-3A Catheter tip 65 0.06 0.06
1780 31/01/2011 CCH ICU Stool 65 + 8 16 ST410
1750 31/01/2011 CCH ICU BAL 65 + 32 8
2106 08/02/2011 CCH ICU Blood 65 + 8 8
2632 20/02/2011 CCH IP-5A Stool 65 + 8 8
2625 20/02/2011 CCH IP-4C Urine 65 + + 16 16
8768 6/4/2011 CCH IP-4B Blood 65 0.008 0.03
4343 17/03/2010 CCH IP-3B CVP-Blood 66 8 16
14611 27/08/2010 CCH ICU CVP Blood 66 + 64 32 ST208
21382 13/12/2010 CCH ICU CVP Culture 66 + 16 4
7052 5/7/2011 CCH ICU BAL 66 + 8 16
634 11/01/2011 CCH ICU Catheter tip 69 + 8 4 ST108
1447 24/01/2011 CCH ICU CVP Culture 69 + 0.5 0.06
161 03/01/2011 CCH PULM Sputum 71 0.06 0.06 ST414
21174 09/12/2010 CCH IP-3A Blood 78 0.03 0.25 ST412
22055 25/12/2010 CCH IP-3C CVP Blood 89 128 128 ST413
679-BAS 04/09/2010 NCI 5th ﬂoor Ear swab 64 + 8 8
P67-AZ 09/01/2011 NCI OP Blood 64 + + 64 16 ST411
9925-SAM 15/12/2010 NCI 7th ﬂoor Blood 64 + 16 8 ST409
P391-AH 14/09/2010 NCI 5th ﬂoor Blood 65 8 16
461-SF 15/12/2010 NCI 7th ﬂoor Blood 65 + 16 32
6332-ABD 02/09/2010 NCI 5th ﬂoor Ear swab 69 + 16 8
5687-SHAY 11/10/2010 NCI 5th ﬂoor Blood 71 0.25 0.25
P38-YSF 04/01/2011 NCI 5th ﬂoor Blood 94 + 64 64 ST331
P49-HAM 05/01/2011 NCI 5th ﬂoor Blood 94 + 8 8
BAL, bronchoalveolar lavage; CVP, central venous port; IMI, imipenem; MER, meropenem.
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MLST
Seven housekeeping genes were ampliﬁed and sequenced as
described above for ten isolates. Ten distinct sequence types (STs)
were identiﬁed, seven of which are novel and assigned ST408–
ST414. The remaining three STs were identiﬁed as ST331, ST108
and ST208. Typing by MLST further illustrated the large diversity
foundwithin the strains, as isolateswith similar blaOXA-51-like genes
had different STs. This is clear for isolates 9925-SAMandNCI-P67,
both were from the NCI and possessed blaOXA-64, but they
belonged to different STs: 409 and 411, respectively. When
compared with another blaOXA-64-positive isolate, 8357, which
was from a patient at CCH, another ST was identiﬁed, ST408.
MIC and carbapenem-hydrolysing class D b-lactamase
(CHDL) genes
The majority of isolates (n = 25), representing 73%, were
resistant to imipenem and/or meropenem (MIC  8 mg/L).
This resistance could be correlated with the presence of the
acquired class-D oxacillinases: blaOXA-23, blaOXA-58 and blaOXA-40
(Table 2).
Genes encoding all three transferable OXA types associated
with resistance were identiﬁed in these strains: blaOXA-23 in 18
isolates, blaOXA-58 in ﬁve isolates and blaOXA-40 in one isolate.
All isolates, except one, possessing blaOXA-23 were resistant to
imipenem and meropenem (MIC  8 mg/L). ISAba1 was
detected upstream of blaOXA-23 in the resistant isolates, hence
providing a promoter for the expression of the gene
(Figure 2). However, this IS element was not found upstream
in the blaOXA-23-containing isolate that was carbapenem
sensitive. The analysis of the A. baumannii outbreak in the
ICU at CCH in early 2011 revealed that although the strains
harboured distinct blaOXA-51-like types and were epidemiolog-
ically different, they all possessed blaOXA-23 as the resistance
mechanism.
10
0
90807060504030
161
5687-SHAY
15 324
1447
634
6332-Abd
21 382
7052
8357
12 435
15 094
22 055
4248
461-SF
4842
14 611
9930
P49-HAM
9925-Sam
1750
1780
P38-YSF
4343
8768
10 262
P391-AH
7947
679-Bas
P67-AZ
21 174
2625
14 298
2106
2632
Sputum
Blood
Catheter tip
CVP 
Catheter tip
Ear Swab
CVP culture
BAL
CVP Blood
Blood
Urine
CVP Blood
CVP
Blood
CVP
CVP Blood
Blood
Blood
Blood
BAL
Stool
Blood
CVP Blood
Blood
CVP
Blood
Sputum
Ear Swab
Blood
Blood
Urine
Catheter tip
Blood
Stool
Pulm
IP-3A
ICU
ICU
NCI-5th floor
ICU
ICU
DSCH
ICU
IP-4B
IP-3C
IP-5C
NCI-7th floor
ICU
ICU
ICU
NCI-5th floor
NCI-7th floor
ICU
ICU
NCI-5th floor
IP-3B
IP-4B
ICU
NCI-5th floor
ICU
NCI-5th floor
DSCH
IP-3A
IP-4C
ICU
ICU
IP-5A
3/1/2011
11/10/2010
9/9/2010
24/1/2011
11/1/2011
2/9/2010
13/12/2010
7/5/2011
19/5/2011
23/7/2010
5/9/2010
25/12/2010
15/3/2010
15/12/2010
23/3/2010
27/8/2010
15/6/2010
5/1/2011
1/11/2010
31/1/2011
13/1/2011
4/1/2011
17/3/2010
4/6/2011
19/6/2010
14/9/2010
17/5/2010
4/9/2010
9/1/2011
9/12/2010
20/2/2011
22/8/2010
8/2/2011
20/2/2011
OXA-71
OXA-71
OXA-65
OXA-69
OXA-69
OXA-66
OXA-66
OXA-66
OXA-64
OXA-64
OXA-65
OXA-1.
OXA-65
OXA-65
OXA-65
OXA-66
OXA-65
OXA-94
OXA-64
OXA-65
OXA-65
OXA-94
OXA-64
OXA-65
OXA-65
OXA-65
OXA-64
OXA-64
OXA-64
OXA-78
OXA-65
OXA-64
OXA-65
OXA-65
FIG. 1. Pulsed ﬁeld gel electrophoresis proﬁle for Acinetobacter baumannii strains in this study, showing the associated isolation site, location, date,
and blaOXA51-like genes.
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blaOXA-58-positive isolates were also found in both hospitals
and all were resistant to meropenem and imipenem, with the
exception of isolate 14298, which was intermediate to merope-
nem (MIC 4 mg/L). The genetic environment of the blaOXA-58
showed that the gene was ﬂanked by two copies of ISAba3
(Figure 2). Two isolates harboured an interrupted sequence of
ISAba3 upstream of the blaOXA-58 gene (L. Al-Hassan, H. El
Mehallawy and S. G. B. Amyes, unpublished results).
A single isolate, 14611 from CCH, was positive for blaOXA-40
and it was also resistant to carbapenems. No insertion element
was detected upstream of the blaOXA-40 gene.
Eight of the 11 isolates that did not harbour acquired
carbapenemase genes were sensitive to carbapenems (MIC
<8 mg/L). One isolate, 22055, lacking these genes was
resistant to carbapenems and harboured the chromosomal
OXA-89 b-lactamase. ISAba2 was found upstream of the
blaOXA-89 gene (Figure 2).
Discussion
Acinetobacter baumannii is a problematic, multidrug-resistant
pathogen identiﬁed in healthcare environments worldwide [1].
The remarkable ability of A. baumannii to capture and express
resistance genes has allowed it to become one of the major
threats in hospitals, as it becomes resistant to all available
antibiotics, including carbapenems [4]. Resistance mechanisms
such as modiﬁcation of target site, efﬂux pumps and enzymatic
inactivation have all been reported in A. baumannii [1]. Of
major concern is the presence of several classes of b-lacta-
mases within the A. baumannii genome. The localization of
these resistance genes on plasmids facilitates their movement
from one bacterium to another [5]. Class D oxacillinase genes:
blaOXA-23, blaOXA-40 and blaOXA-58 have been repeatedly
reported in A. baumannii outbreaks from different parts of
the world [1,19].
The construction of a linkage map based on the intrinsic
OXA-51-like b-lactamases was reported by Evans et al. [7].
The sequence relationship was determined for 37 distinct
members of the OXA-51-like b-lactamase family. This study
identiﬁed three large groups around OXA-66, OXA-69 and
OXA-98 in addition to other unrelated branched enzymes [7].
In the current study a large diversity was found in the
sequences of blaOXA-51-like with eight different gene variants
identiﬁed. This is particularly interesting given the short
duration of isolate collection (1 year) as well as the isolates
deriving from only two hospitals. In fact seven different
blaOXA-51-like genes were identiﬁed in CCH alone. When
looking at the distribution of blaOXA-51-like genes in the linkage
map, it is clear that they have different origins as the genes
identiﬁed are not clustered in closely related groups. Fourteen
isolates, accounting for 41%, harboured blaOXA-65, which
according to the linkage map forms a ‘central hub’ from which
all other groups radiate and is thought to be ancestral to all
blaOXA-51-like genes [7]. This subsequently indicates the pres-
ence of the potential ancestral blaOXA-51-like gene in A. bau-
mannii in Egypt, which is in the current collection of strains and
is the major gene identiﬁed. Additionally, this may explain that
the large diversity found is an outcome of the evolution of the
ancestral blaOXA-65 gene in some cases, rather than the of
‘foreign carriage’ of clones into the country.
blaOXA-69, blaOXA-66 and blaOXA-71 have been associated with
Worldwide [European] Clones I, II and III, respectively, and all
have been identiﬁed in the current study [6,7]. blaOXA-66 and
blaOXA-71 genes were identiﬁed in both hospitals, which may
indicate local distribution in Egyptian hospitals. blaOXA-69, on
the other hand, was found in two isolates in the ICU outbreak
in early 2011 at CCH only. This illustrates the extent of spread
of the major lineages of A. baumannii.
blaOXA-89 is a member of the blaOXA-98 cluster and contains
the resultant protein showing three amino acid substitutions
from OXA-98. In the current study, one isolate from CCH
was found positive for blaOXA-89, and harboured ISAba2
upstream. The presence of an insertion sequence upstream
of other blaOXA-51-like genes has been reported to enhance the
expression and cause resistance to carbapenems [20, 21].
ISAba2 has only been reported upstream of blaOXA58 [22].
With no other resistance mechanism identiﬁed, the presence
of ISAba2 was responsible for high-level resistance to both
imipenem and meropenem (MIC 128 mg/L and 256 mg/L,
respectively). Furthermore, this shows the ability of IS to insert
upstream of these genes and act as promoters.
blaOXA genes that are not part of previously identiﬁed clusters
have also been identiﬁed in the current study: blaOXA–94 in two
fxsA         ISAba2 blaOXA-89
OXA-23
   IS
 ISAba1                  bla
Aba3             blaOXA-58            ISAba3
FIG. 2. Schematic representation showing examples of the genetic
environments of blaOXA-89, blaOXA-23 and blaOXA-58.
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isolates from the NCI and blaOXA-64 in eight isolates from both
hospitals. OXA-64 is closely related to OXA-71 and is now
commonly found in theMiddle East [7, 9] (A. Al-Hasan and S.G.B.
Amyes, unpublished results). blaOXA-94, on the other hand,
forms a branch of blaOXA-65 cluster with three amino acid
substitutions in the resultant protein.
As expected from this large diversity of isolates, there is
considerable variation in their PFGE proﬁles. Notably, isolates
harbouring similar blaOXA-51-like genes have different PFGE
proﬁles and no epidemiological linkage can be inferred. This
could be a result of the localization of the patients in different
wards and at different times in the hospital. Even for isolates
recovered from the ICU at different times, there seems to be
signiﬁcant variability in proﬁles suggesting the presence of
different clones within the same hospital. Turton et al. found a
correlation between PFGE and sequence typing, in contrast to
Evans et al. who later noted major differences between PFGE
typing and sequence typing in their study [7,23].
MLST further illustrated the diversity within the isolates as
eight out of ten isolates typed were assigned to novel STs.
Previous reports have shown that typing with blaOXA-51-like was
more consistent with MLST than with PFGE [8]. In the current
study, isolates 8357, P67-AZ and 9925-SAM had similar
blaOXA-51-like genes but, when they were typed with MLST,
they showed three different novel STs, 408, 409 and 411,
respectively. The PFGE patterns were also different for these
isolates. This could indicate the presence of three distinct
clones in the two hospitals, especially that they were isolated
in different months and in different wards. MLST, in this case,
correlated with the epidemiological data of PFGE. Hamouda
et al. [8] found MLST to be more accurate than PFGE when
studying isolates on a global scale.
Seventy-three percent of the isolates were resistant to
carbapenems, and this is associated with all three CHDL genes
found in this study. Different genetic structures are associated
with the upstream environment of blaOXA-58 and blaOXA-23 and
they have been identiﬁed in different regions of the world
[22,24]. In the current study, blaOXA-23 is associated with
ISAba1 in the upstream environment and blaOXA-58 is ﬂanked
by ISAba3. The effective mobilization of these genes by
insertion sequences upstream together with the localization
on plasmid largely contribute the spread of these resistance
genes [4].
In conclusion, the data presented show the large diversity of
A. baumannii isolated from two centres in Cairo, Egypt. The
genetic plasticity of A. baumannii is represented by the
presence of several insertion sequences upstream of the
resistance genes, thereby facilitating the expression and
causing resistance to carbapenems. Several clones seem to
be present in Egyptian hospitals requiring increased awareness
of the healthcare personnel and stricter infection control
policies to prevent the dissemination of these isolates.
Nucleotide Sequence Accession Number
The ISAba2-blaOXA-89 sequence of strain 22055 has been
deposited under the accession number JX499236.
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